SBIR-STTR Award

Selection and Development of a Lead Biologic for Treating Mitochondrial Disorders
Award last edited on: 3/25/19

Sponsored Program
STTR
Awarding Agency
NIH : NIA
Total Award Amount
$241,568
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Blake Hill

Company Information

Cytegen Corporation

4230 North Oakland Avenue Unit 154
Milwaukee, WI 53211
   (650) 473-0701
   nfo@cytegen.com
   www.cytegen.com

Research Institution

Medical College of Wisconsin

Phase I

Contract Number: 1R41AG059530-01
Start Date: 6/15/18    Completed: 5/31/19
Phase I year
2018
Phase I Amount
$241,568
Mitochondrial dysfunction causes mitochondrial diseases and is tightly linked to aging and neurodegenerative disorders such as Parkinson's and Alzheimer's. Recent discoveries support that mitochondrial dysfunction can be overcome to treat age-related decline. CyteGen's hypothesis is that exercise induces the secretion of blood- borne proteins that act systemically to stimulate removal of damaged mitochondria and enrichment of healthy mitochondria (mitochondrial fitness). The company's goal is to identify these proteins to develop into biologics that would serve as a platform to treat the myriad of diseases associated with mitochondrial dysfunction. The discovery platform builds on existing work that exercise reversed mitochondrial dysfunction in a mouse model for mitochondrial disease. In this application, the candidate factors are tested in a cell-based mitochondrial respiration assay in Aim 1 and evaluated known agonists of mitochondrial biogenesis [bezafibrate and the glitazones (PPAR agonists); metformin and AICAR (AMPK); and resveratrol (Sirt1)]. The results will be a rank ordering of each candidate factor based on their ability to improve respiration. In Aim 2, false positives will be eliminated through commonplace assays to assess mitochondrial morphological analyses, mtDNA copy number, and expression of mitochondrial quality control proteins. These data will winnow the list to a lead biologic candidate for Phase II development in pre-clinical models and translation into clinical trials.

Project Terms:
Affect; age related; Aging; Agonist; Alzheimer's Disease; Automobile Driving; base; Bayesian Analysis; Bezafibrate; Biogenesis; Biological Assay; Blood; Cardiomyopathies; Cells; Chronic progressive external ophthalmoplegia; Clinical; Clinical Trials; cognitive function; Collaborations; Data; Data Set; Defect; Development; Diabetes Mellitus; Disease; DNA biosynthesis; DNA copy number; DNA polymerase gamma; DNA Sequence Alteration; DNA-Directed DNA Polymerase; Dose; Drug Kinetics; early onset; Endogenous Factors; endurance exercise; Engineering; Evaluation; Excision; Exercise; Genes; Genus Hippocampus; Goals; Government; Heart failure; Hereditary Disease; Impairment; improved; Individual; Intervention; Laboratories; Lead; lead candidate; Link; Malignant Neoplasms; Measures; medical schools; Metformin; Methods; Mitochondria; Mitochondrial Diseases; Mitochondrial DNA; mitochondrial dysfunction; mitochondrial fitness; Mitochondrial Proteins; Modeling; Morphology; mouse model; Mus; Muscle; Mutant Strains Mice; Mutation; Nerve Degeneration; Neurodegenerative Disorders; Neuromuscular Diseases; new technology; novel; Parkinson Disease; Pathologic; Pathway interactions; Patients; Peroxisome Proliferator-Activated Receptors; Persons; Pharmacology; Phase; Polymerase; Pre-Clinical Model; Property; Protein Analysis; Protein Engineering; protein expression; Protein Secretion; Proteins; Proteomics; Quality Control; repaired; Respiration; Resveratrol; reverse genetics; sedentary; Serum; SIRT1 gene; Synaptic plasticity; Syndrome; Testing; Therapeutic; Thiazolidinediones; Tissues; Translations; Universities; Wild Type Mouse; Wisconsin; Work;

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----